PrograMS
Recruiting
- Conditions
- Multiple Sclerosis
- Registration Number
- NL-OMON21916
- Lead Sponsor
- VU University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 260
Inclusion Criteria
All people with MS and all healthy controls who have previously participated in the Presto (local ethics committee number: 2002/140), GeneOCT (2004/9), or LTD (2010/336) studies (collectively also known as the Amsterdam MS Cohort”) and have not provided objection to be contacted for follow-up study, or have been enquired to join the cohort based on the Amsterdam MS Cohort (2020/269) protocol.
Exclusion Criteria
MS patients unable to undergo the minimal data collection (as described in Methods section) or comorbidity that interferes with participation in this study (controls).
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Our primary outcome is longitudinal cognitive decline, as measured by neuropsychological assessment (NPE).
- Secondary Outcome Measures
Name Time Method Our secondary outcome is clinical progression, defined by worsening physical disability (EDSS). Parameters/predictors: Functional brain changes (functional MRI and magnetoencephalography, MEG); structural brain changes (MRI), ophthalmologic measurements (optical coherence tomography – OCT, and eye movements) and blood biomarkers.